Although extreme thrombocytosis occurs rarely, researchers were able to identify its underlying cause and potential prognosis for patients who develop the condition.
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.